Table 3.
Estimated harmonized serum concentration of sertraline and N-desmethylsertraline and metabolic ratio (MR) in different genotype-predicted CYP2C19 phenotype subgroups (NM reference subgroup in statistical analyses)
| Subgroup | Patients (n) | Samples (n) | Sertraline (nM) harmonized to 100 mg/day (95% CI) | Fold changea | p | N-desmethylsertraline (nM) harmonized to 100 mg/day (95% CI) | Fold changea | p | MR (95% CI) | Fold changea | p |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UM | 351 | 604 | 92.7 (85.1–101.1) | 0.89 | 0.012 | 144.2 (133.1–158.9) | 0.91 | 0.016 | 1.491 (1.374–1.610) | 1.03 | 0.517 |
| NM | 495 | 918 | 103.6 (91.8–116.8) | — | — | 159.2 (142.5–177.9) | — | — | 1.453 (1.270–1.635) | — | — |
| IM | 321 | 580 | 142.9 (130.8–156.2) | 1.38 | <0.001 | 234.3 (215.7–254.4) | 1.47 | <0.001 | 1.658 (1.537–1.779) | 1.14 | <0.001 |
| PM | 35 | 88 | 277.4 (224.1–343.5) | 2.68 | <0.001 | 477.9 (391.8–582.9) | 3.00 | <0.001 | 1.835 (1.547–2.123) | 1.26 | 0.009 |
Linear mixed model analysis was adjusted for age (p < 0.001), gender (<0.001) and time between last dose administration and serum sampling (p < 0.001). To convert nmol/L to ng/mL, multiply by a factor of 3.27 and 3.43 for sertraline and N-desmethylsertraline, respectively
aDifference compared with noncarriers (*1/*1)